Ancora L&G makes first life science real estate acquisition in US

Ancora L&G makes first life science real estate acquisition in US

Ancora L&G, a newly formed joint venture between UK-based asset management company Legal & General Group’s alternative asset platform Legal & General Capital (LGC) and US-based real estate developer Ancora, has secured its first US science and technology real estate projects.

Through an initial seed capital investment of $500 million from LGC, Ancora L&G will be capitalised to deliver $4 billion of existing US pipeline and planned acquisition and development activity over the next five years.

Marking the first acquisition for the new partnership, Ancora L&G has, acquired 387 Technology Circle NW, a 128,000 sq ft Class A life science/lab building in the Science Square Innovation District adjacent to Georgia Institute of Technology’s (GeorgiaTech) campus in Atlanta, Georgia. The project meets its ambition to invest in and build a premium portfolio of science and technology assets in emerging US markets, in partnership with high quality anchor institutions.

Atlanta is a top 25 US life science cluster market with strong forecast growth over the next 10 years, according to L&G. Georgia

Tech’s capabilities in research and commercialisation; the emerging life sciences/tech industry in Atlanta; and its economic dynamism, make for strong demand indicators at site, the company said. The asset is currently fully let and occupied by four tenants: Georgia Tech, CardioMEMS, Kemira Chemicals, and VERO Biotech.

”The US is the world’s largest real estate market at c.$9 trillion in value. However, the lab real estate market in particular comprises only 166 million sq ft – one of the smallest sectors among other commercial asset classes. This lack of scale creates high barriers to entry for investors and it has been particularly challenging for tenants to grow due to scarcity of supply. Legal & General’s ability to access this opportunity via Ancora sets it apart from other sources of institutional capital seeking to participate in the market,” said L&G in a statement.

LGC has a strong track record of establishing and scaling up innovative businesses and has led the way in driving science and technology growth through its Bruntwood SciTech partnership, the UK’s leading developer of innovation districts. Bruntwood SciTech has quickly expanded over 11 UK locations, a model LGC will look to replicate across the US in partnership with Ancora. 

In line with this ambition, Ancora L&G has recently been selected as the preferred developer of a public health laboratory in Providence. An 80,000 sq ft state-of-the-art laboratory, funded by the U.S. Centers for Disease Control, will anchor the project and Brown University has also signed a letter of intent to lease 20,000 sq ft of private laboratory space.

To support future growth of Ancora L&G, LGC is seeking third party co-investment partners to grow the business at scale. As with a number of LGC investments, LGC aims to finance longer term cashflows by using them to back its annuity business, providing better value for policyholders and greater financing for investors.

As LGC drives forward its ambition to internationalise, it is a testament to the business’s investment appetite and the quality of our teams that we have secured our first projects just months after forming the new Ancora L&G joint venture. The development in Georgia is an exemplar of the types of projects we will look to invest in, located in areas of significant growth potential with high quality anchor institutions as key stakeholders in each project. They build significant momentum for future growth of the Ancora L&G partnership, while laying the groundwork for LGC’s wider US expansion,” said Wes Erlam, Managing Director of Urban Regeneration, Legal & General Capital.

“These new projects are a significant start to our partnership with Legal & General. With the addition of new lab space and our backing by established anchor institutions, we are pleased that our partnership is already delivering real results for both our US clients and UK investors. With the appetite for more investment and building of new sites, we look forward to a positive momentum as we move forward with our growth plans,” Josh Parker, CEO Ancora Legal & General.